Inspired by the empowerment song ‘This is Me’ – originally sung ... This Rare Disease Day, Sanofi is also inviting people to learn more about 'Rare. We Are Many.’ in support of the ...
Sanofi has added another dimension to the use ... built from various private and public data sources, according to Le Song, the AI specialist’s chief technology officer. The Menlo Park and ...
Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...
Despite receiving a prior wrist slap from the FDA in the shape of a Form 483, Sanofi is still working to right the ship at a U.S. drug ingredients plant tied to its longstanding subsidiary Genzyme.
Sanofi's participation at the JP Morgan 43rd Annual Healthcare Conference on 14 January 2025 was marked by a comprehensive overview of the company's position in 2024 and its strategic vision for t ...
Sanofi (SNYNF – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from Bank of America Securities reiterated a Buy rating on the ...
French pharmaceutical giant Sanofi has received a warning letter from the U.S. Food and Drug Administration following an inspection at its drug manufacturing facility in Framingham. French ...
The Food and Drug Administration has warned Sanofi about a series of “significant” manufacturing problems, including contamination, at a key facility in Massachusetts where the company makes ...
AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company takes its lead candidate through a prostate cancer trial. The Pb-212 ...
Also Read: Sanofi’s Blood Cancer Drug’s New Subcutaneous Formulation Hits Primary Goal In Late-Stage In Multiple Myeloma The facility’s quality unit was also scrutinized for its inability to ...
Hosted on MSN23d
'The next battleground': Sanofi exploring opportunities in second generation obesity drugsPaul Hudson, CEO of Sanofi, says his firm is exploring the second generation of obesity drugs, noting that solutions for sustained weight loss were "the next battleground." Irv Gotti, Music ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results